Relationship of biochemically persistent disease and thyroglobulin-doubling time to age at surgery in patients with papillary thyroid carcinoma

Endocrine Journal

Volumn 60, Issue 4, 2013, Pages 415-421

  Miyauchi, Akira ^a   Kudo, Takumi ^a   Kihara, Minoru ^a   Higashiyama, Takuya ^a   Ito, Yasuhiro ^a   Kobayashi, Kaoru ^a   Miya, Akihiro ^a  

^a KUMA HOSPITAL   (Japan)

Author keywords

Age at surgery; Biochemically persistent disease; Papillary thyroid carcinoma; Thyroglobulin doubling time

Indexed keywords

THYROGLOBULIN;

ADOLESCENT; ADULT; AGE; AGE AT SURGERY; AGE DISTRIBUTION; AGED; ANALYTICAL PARAMETERS; ARTICLE; BIOCHEMICALLY PERSISTENT DISEASE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GERIATRIC PATIENT; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; POSTOPERATIVE PERIOD; THYROGLOBULIN DOUBLING TIME; THYROID CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; CARCINOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LOGISTIC MODELS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROGNOSIS; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR BURDEN; YOUNG ADULT;

EID: 84876972390     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ito Y, Miyauchi A (2009) Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid. Endocr J 56: 177-192.
2. Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K, et al. (2012) Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J Surg 36: 1274-1278.
3. Wu HS, Young MT, Ituarte PH, D'Avanzo A, Duh QY, et al. (2000) Death from thyroid cancer of follicular cell origin. J Am Coll Surg 191: 600-606.
4. Ito Y, Miyauchi A, Jikuzono T, Higashiyama T, Takanura Y, et al. (2007) Risk factors contributing to a poor prognosis of papillary thyroid carcinoma: Validity of UICC/AJCC TNM classification and stage grouping. World J Surg 31: 838-848.
5. Toniato A, Boschin I, Casara D, Mazzarotto R, Rubello D, et al. (2008) Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol 15: 1518-22.
6. Eichhorn W, Tabler H, Lippold R, Lochmann M, Schreckenberger M, et al. (2003) Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution. Thyroid 13: 949-958.
7. Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K, et al. (2012) Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph node, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J Surg 36: 1274-1278.
8. Hung W, Sarlis NJ (2002) Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid 12: 683-702.
9. Mazzaferri EL, Jhiang S (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: 418-428.
10. Kloos RT, Mazzaferri EL (2005) A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90: 5047-5057.
11. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, et al. (2006) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91: 926-932.
12. Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, et al. (2011) Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 21: 707-716.
13. th ed. Wiley-Blackwell, Oxford, UK: 58-62.
14. Cady B, Rosai R (1988) An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery 104: 947-953.
15. Hay ID, Grant CS, Taylor WF, McConahey WM (1987) Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102: 1088-1095.
16. Hay ID, Bergstalh EJ, Goellner JR, Ebersokd JR, Grant CG (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114: 1050-1058.
17. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY (2007) Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg 245: 366-378.
18. th ed, Lippincott Williams & Wilkins, Philadelphia, USA: 934-966.
19. Miyauchi A, Onishi T, Morimoto S, Takai S, Matsuzuka F, et al. (1984) Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg 199: 461-466.
20. Tomoda C, Miyauchi A (2012) Undetectable serum thyrogloblin levels om patients with megullary thyroid carcinoma after total thyroidectomy without radioiodine ablation. Thyroid 22: 680-682.
21. Miyauchi A, Matsuzuka F, Kuma K, Takai S, Nakamoto K, et al. (1988) Evaluation of surgical results and prediction of prognosis in patients with medullary thyroid carcinoma by analysis of serum calcitonin levels. World J Surg 12: 610-615.
22. Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF; GTE Study Group (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doublingtimes in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90: 6077-6084.
23. Collins VP, Loeffler RK, Tivey H (1956) Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med 76: 988-1000.